An official website of the United States government
Home
Name
Pomalidomide
Alternate Names
CC-4047
Pomalyst
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
TNF-alpha production inhibitor/thalidomide analogue
NSC Number
767909
Primary Site
Multiple myeloma
Histology
None
Remarks
February 8, 2013: FDA approved pomalyst as a treatment for relapsed and refractory multiiple myeloma for patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of last therapy. . This drug is a derivative of thalidomide that is anti-angiogenic and also acts as an immunomodulator.
May 14, 2020: The FDA expanded the indication of pomalidomide (POMALYST) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative.
May 14, 2020: The FDA expanded the indication of pomalidomide (POMALYST) to include treating adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and Kaposi sarcoma in adult patients who are HIV-negative.
Coding
This drug should be coded
